albuterol has been researched along with Bronchopulmonary Dysplasia in 22 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 9.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| "To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm." | 7.68 | Safety of continuous nebulized albuterol for bronchospasm in infants and children. ( Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993) |
| "Aerosolized albuterol is widely used, but its tolerability and efficacy in infants with severe bronchopulmonary dysplasia (sBPD) is not well established." | 5.41 | Tolerability and efficacy of two doses of aerosolized albuterol in ventilated infants with BPD: A randomized controlled crossover trial. ( Dysart, K; Jensen, E; Napolitano, N; Panitch, H; Soorikian, L; Zhang, H, 2021) |
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 5.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| "To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm." | 3.68 | Safety of continuous nebulized albuterol for bronchospasm in infants and children. ( Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993) |
| "Albuterol is a specific beta-2 agonist that has been reported to be effective in treating infants and children with bronchospastic pulmonary disease." | 2.67 | A randomized placebo-controlled study to evaluate the effects of oral albuterol on pulmonary mechanics in ventilator-dependent infants at risk of developing BPD. ( Bhutani, VK; Fox, WW; Stefano, JL, 1991) |
| "IL-1Ra treatment prevented hyperoxia-induced alveolar disruption and airway fibrosis but, surprisingly, not the increase in methacholine-induced airway contraction." | 1.43 | Airway Remodeling and Hyperreactivity in a Model of Bronchopulmonary Dysplasia and Their Modulation by IL-1 Receptor Antagonist. ( Bourke, JE; Bui, C; Donovan, C; Lam, M; Lamanna, E; Nold, MF; Nold-Petry, CA; Royce, SG; Rudloff, I, 2016) |
| "We used a placebo-controlled standardized protocol to define the dose-response relationship to the beta-adrenergic bronchodilator salbutamol (albuterol) in 10 ventilator-dependent premature infants at a postnatal age of 13." | 1.28 | Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants. ( Dehan, M; Denjean, A; Gaultier, C; Guimaraes, H; Migdal, M; Miramand, JL, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.64) | 18.7374 |
| 1990's | 10 (45.45) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Napolitano, N | 1 |
| Dysart, K | 1 |
| Soorikian, L | 1 |
| Zhang, H | 1 |
| Panitch, H | 1 |
| Jensen, E | 1 |
| Slaughter, JL | 1 |
| Stenger, MR | 1 |
| Reagan, PB | 1 |
| Jadcherla, SR | 1 |
| Royce, SG | 1 |
| Nold, MF | 1 |
| Bui, C | 1 |
| Donovan, C | 1 |
| Lam, M | 1 |
| Lamanna, E | 1 |
| Rudloff, I | 1 |
| Bourke, JE | 1 |
| Nold-Petry, CA | 1 |
| Durlak, W | 1 |
| Klimek, M | 1 |
| Kwinta, P | 1 |
| Wu, B | 1 |
| Nielson, DW | 1 |
| Hayes, D | 1 |
| Kriss, VM | 1 |
| Iocono, JA | 1 |
| Dixon, BJ | 1 |
| Collins, PB | 1 |
| Ballard, HO | 1 |
| Robin, B | 1 |
| Kim, YJ | 1 |
| Huth, J | 1 |
| Klocksieben, J | 1 |
| Torres, M | 1 |
| Tepper, RS | 1 |
| Castile, RG | 1 |
| Solway, J | 1 |
| Hershenson, MB | 1 |
| Goldstein-Filbrun, A | 1 |
| Halvorsen, T | 1 |
| Skadberg, BT | 1 |
| Eide, GE | 1 |
| Røksund, OD | 1 |
| Carlsen, KH | 1 |
| Bakke, P | 1 |
| Pfenninger, J | 1 |
| Aebi, C | 1 |
| Katz, RW | 1 |
| Kelly, HW | 1 |
| Crowley, MR | 1 |
| Grad, R | 1 |
| McWilliams, BC | 1 |
| Murphy, SJ | 1 |
| Fok, TF | 2 |
| Monkman, S | 1 |
| Dolovich, M | 1 |
| Gray, S | 1 |
| Coates, G | 1 |
| Paes, B | 1 |
| Rashid, F | 1 |
| Newhouse, M | 1 |
| Kirpalani, H | 2 |
| De Boeck, K | 1 |
| Smith, J | 1 |
| Van Lierde, S | 1 |
| Devlieger, H | 1 |
| Lam, K | 1 |
| Ng, PC | 1 |
| So, HK | 1 |
| Cheung, KL | 1 |
| Wong, W | 1 |
| So, KW | 1 |
| Denjean, A | 2 |
| Paris-Llado, J | 1 |
| Zupan, V | 1 |
| Debillon, T | 1 |
| Kieffer, F | 1 |
| Magny, JF | 1 |
| Desfrères, L | 1 |
| Llanas, B | 1 |
| Guimaraes, H | 2 |
| Moriette, G | 1 |
| Voyer, M | 1 |
| Dehan, M | 2 |
| Breart, G | 1 |
| Pianosi, PT | 1 |
| Fisk, M | 1 |
| Migdal, M | 1 |
| Miramand, JL | 1 |
| Gaultier, C | 1 |
| Stefano, JL | 1 |
| Bhutani, VK | 1 |
| Fox, WW | 1 |
| Koren, G | 1 |
| Schmidt, B | 1 |
| Tan, Y | 1 |
| Santos, R | 1 |
| Soldin, S | 1 |
| Kraemer, R | 1 |
| Schöni, MH | 1 |
| Rotschild, A | 1 |
| Solimano, A | 1 |
| Puterman, M | 1 |
| Smyth, J | 1 |
| Sharma, A | 1 |
| Albersheim, S | 1 |
| Wilkie, RA | 1 |
| Bryan, MH | 1 |
| Kasian, GF | 1 |
| Ninan, A | 1 |
| Duncan, WJ | 1 |
| Bingham, WT | 1 |
| Mersal, A | 1 |
| Tyrrell, MJ | 1 |
| Sankaran, K | 1 |
11 trials available for albuterol and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Tolerability and efficacy of two doses of aerosolized albuterol in ventilated infants with BPD: A randomized controlled crossover trial.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Bronchopulmonary Dysplasia; Cross-Over | 2021 |
Pulmonary function in bronchopulmonary dysplasia.
Topics: Airway Obstruction; Albuterol; Bronchodilator Agents; Bronchopulmonary Dysplasia; Child, Preschool; | 2004 |
Respiratory response to salbutamol (albuterol) in ventilator-dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection.
Topics: Administration, Inhalation; Aerosols; Albuterol; Blood Gas Analysis; Blood Gas Monitoring, Transcuta | 1993 |
Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia.
Topics: Aerosols; Albuterol; Bronchopulmonary Dysplasia; Cross-Over Studies; Dose-Response Relationship, Dru | 1996 |
Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia.
Topics: Administration, Inhalation; Airway Resistance; Albuterol; Bronchodilator Agents; Bronchopulmonary Dy | 1998 |
Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease.
Topics: Administration, Intranasal; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; Blood Gas Mon | 1998 |
Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study.
Topics: Administration, Inhalation; Albuterol; Beclomethasone; Bronchodilator Agents; Bronchopulmonary Dyspl | 1998 |
A randomized placebo-controlled study to evaluate the effects of oral albuterol on pulmonary mechanics in ventilator-dependent infants at risk of developing BPD.
Topics: Albuterol; Bronchopulmonary Dysplasia; Caffeine; Double-Blind Method; Heart Rate; Humans; Infant, Ne | 1991 |
Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia.
Topics: Airway Resistance; Albuterol; Biomechanical Phenomena; Bronchopulmonary Dysplasia; Hemodynamics; Hum | 1990 |
Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia.
Topics: Albuterol; Blood Pressure; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Double-Blind Method | 1989 |
Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia.
Topics: Albuterol; Bronchopulmonary Dysplasia; Child, Preschool; Diltiazem; Humans; Hydralazine; Hypertensio | 1988 |
11 other studies available for albuterol and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Inhaled bronchodilator use for infants with bronchopulmonary dysplasia.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Bronchopulmonary Dysplasia; Cohort Stu | 2015 |
Airway Remodeling and Hyperreactivity in a Model of Bronchopulmonary Dysplasia and Their Modulation by IL-1 Receptor Antagonist.
Topics: Airway Remodeling; Albuterol; Animals; Bronchial Hyperreactivity; Bronchopulmonary Dysplasia; Diseas | 2016 |
Regional lung ventilation pattern in preschool children with bronchopulmonary dysplasia is modified by bronchodilator response.
Topics: Albuterol; Bronchodilator Agents; Bronchopulmonary Dysplasia; Child, Preschool; Electric Impedance; | 2017 |
Should inhaled beta-agonists or lung function testing be routine in prematurely born infants with chronic lung disease?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Bronchopulmonary Dysplasia; Chronic | 2008 |
Varicose bronchiectasis and bronchopulmonary dysplasia.
Topics: Albuterol; Bronchiectasis; Bronchodilator Agents; Bronchopulmonary Dysplasia; Chest Wall Oscillation | 2009 |
Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study.
Topics: Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchopulmon | 2004 |
Safety of continuous nebulized albuterol for bronchospasm in infants and children.
Topics: Acute Disease; Albuterol; Asthma; Bronchial Spasm; Bronchiolitis; Bronchopulmonary Dysplasia; Child, | 1993 |
High frequency ventilation trial. Nine year follow up of lung function.
Topics: Albuterol; Bronchodilator Agents; Bronchopulmonary Dysplasia; Child; Female; Follow-Up Studies; High | 2000 |
Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants.
Topics: Aerosols; Albuterol; Bronchoconstriction; Bronchopulmonary Dysplasia; Dose-Response Relationship, Dr | 1992 |
Improvement from pulmonary hyperinflation and bronchial obstruction following sympathomimetics systemically given in infants with broncho-pulmonary diseases.
Topics: Airway Resistance; Albuterol; Bronchitis; Bronchopulmonary Dysplasia; Cystic Fibrosis; Humans; Hyali | 1990 |
Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease.
Topics: Airway Resistance; Albuterol; Bronchodilator Agents; Bronchopulmonary Dysplasia; Chronic Disease; Dr | 1987 |